Cytokeratin 19 fragment predicts the efficacy of epidermal growth factor receptor-tyrosine kinase inhibitor in non-small-cell lung cancer harboring EGFR mutation.

doi:10.1097/JTO.0b013e31828c3929

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Cytokeratin 19 fragment predicts the efficacy of epidermal growth factor receptor-tyrosine kinase inhibitor in non-small-cell lung cancer harboring EGFR mutation.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Jul 2013

Tanaka Kosuke, Hata Akito, Kaji Reiko, Fujita Shiro, Otoshi Takehiro, Fujimoto Daichi, Kawamura Takahisa, Tamai Koji, Takeshita Jumpei, Matsumoto Takeshi, Monden Kazuya, Nagata Kazuma, Otsuka Kyoko, Nakagawa Atsushi, Tachikawa Ryo, Otsuka Kojiro, Tomii Keisuke, Katakami Nobuyuki

Abstract excerpt

BACKGROUND: EGFR gene mutation is independently associated with a favorable response in non-small-cell lung cancer (NSCLC) patients receiving epidermal growth factor receptor -tyrosine kinase inhibitors (EGFR-TKIs), regardless of sex or smoking history. Squamous cell carcinoma patients harboring EGFR mutations show a significantly worse response to EGFR-TKIs compared with adenocarcinoma patients. We hypothesized...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antigens, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoembryonic Antigen

Share to Carcinoma, Large Cell

Share to Erlotinib Hydrochloride

Share to Gefitinib

Share to Keratin-19

Share to Luminescent Measurements

Share to Quinazolines

Source

Open in PubMed

Identifiers

PMID: 23591159
DOI: 10.1097/JTO.0b013e31828c3929

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cytokeratin 19 fragment predicts the efficacy of epidermal growth factor receptor-tyrosine kinase inhibitor in non-small-cell lung cancer harboring EGFR mutation.PMID 23591159Read ↗

[Serum CYFRA21-1 is Correlated with the Efficacy of Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor in Non-small Cell Lung Cancer Patients Harboring EGFR Mutations].Semantic proximity Read ↗

Prognostic value of CYFRA 21 - 1 and Ki67 in advanced NSCLC patients with wild-type EGFR.Semantic proximity Read ↗

Predictive and Prognostic Value of CYFRA 21-1 for Advanced Non-small Cell Lung Cancer Treated with EGFR-TKIs.Semantic proximity Read ↗

Prognostic and predictive value of carcinoembryonic antigen and cytokeratin-19 fragments levels in advanced non-small cell lung cancer patients treated with gefitinib or erlotinib.Semantic proximity Read ↗

Predictive role of CEA and CYFRA 21-1 in patients with advanced-stage NSCLC treated with erlotinib.Semantic proximity Read ↗

Distinction of ALK fusion gene- and EGFR mutation-positive lung cancer with tumor markers.Semantic proximity Read ↗

[Value of carcinoembryonic antigen levels in predicting the efficacy of EGFR-TKI in advanced non-small cell lung cancer harboring EGFR mutations].Semantic proximity Read ↗

Serum fragment of cytokeratin subunit 19 measured by CYFRA 21-1 immunoradiometric assay as a marker of lung cancer.Semantic proximity Read ↗

Predictive and prognostic value of preoperative serum tumor markers is EGFR mutation-specific in resectable non-small-cell lung cancer.Semantic proximity Read ↗

Clinical and molecular characteristics of non-small-cell lung cancer (NSCLC) harboring EGFR mutation: results of the nationwide French Cooperative Thoracic Intergroup (IFCT) program.Semantic proximity Read ↗

Association between EGFR exon 19 or exon 21 mutations and survival rates after first‑line EGFR‑TKI treatment in patients with non‑small cell lung cancerSemantic proximity Read ↗

The prognostic value of serum CA 19-9 for patients with advanced lung adenocarcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.